Casgevy gains UK label expansion for younger patient population
Vertex Pharmaceuticals and CRISPR Therapeutics have secured a label expansion for their gene editing therapy Casgevy (exagamglogene autotemcel) from UK…
30 Oct 2026
Eli Lilly’s tirzepatide outperforms big pharma companies in Q3
Eli Lilly posted another strong quarter fuelled by its obesity franchise medications, with company revenue soaring 39% compared to Q3 in 2025. Lilly has become the dominant big pharma company…
30 Oct 2026
Glenmark opens Allentown distribution hub in US
Glenmark Pharmaceuticals has inaugurated an approximately 160,000ft² distribution hub in Allentown, Pennsylvania, US, consolidating all of its American shipping operations into a single location. Set across a 6.5-acre site, the facility…
30 Oct 2026
Dren Bio raises $350m for dibotatug clinical development
Dren Bio has secured $350m in an oversubscribed private financing round to advance its primary investigational therapy, dibotatug (DR-01), via late-stage clinical evaluation, regulatory submission, and potential commercialisation. The privately…
29 Oct 2026
RFK Jr backs compounding of six unapproved peptides in new policy
US health secretary Robert F Kennedy Jr (RFK Jr) has debuted a policy that allows specific licensed professionals to use a range of unapproved wellness peptides in compounding. Through RFK…
29 Oct 2026
UK Budget light on life sciences but more doors open for biotech startups
The UK Autumn Budget offered little in the way of new measures specifically for the life sciences sector, though incentives for early-stage businesses could help certain biotechs looking to establish…
29 Oct 2026
Enthorin and Rumi sign agreement for FXS therapy
Enthorin Therapeutics has signed an option-to-license agreement with Rumi Therapeutics to advance ENT-7340 for Fragile X syndrome (FXS), as well as other intellectual and developmental disabilities. Under the deal, Rumi…